OROS hydromorphone prolonged release (Jurnista) is a once-daily formulation of hydromorphone that utilizes OROS (osmotic-controlled release oral delivery system) technology to deliver the drug at a near constant rate.
- TRADE NAMES: Dilaudid (AbbVie); Dilaudid-HP; Exalgo (Mallinckrodt); HydroStat IR; Jurnista (Janssen-Cilag); Palladone (Napp)
- INDICATIONS: Pain
- CLASS: Opiate agonist
- HALF-LIFE: 1–3 hours; 2 hours (IV)
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Alvimopan, Ammonium chloride, Amphetamines, Anticholinergics, Anxiolytics and hypnotics, Buprenorphine, Butorphanol, Cimetidine, CNS depressants, Desmopressin, Domperidone, Droperidol, Linezolid, MAO inhibitors, Metoclopramide, Moclobemide, Nalbuphine, Pegvisomant, Pentazocine, Phenothiazines, Sodium Oxybate, SSRIs, St John's Wort, Succinylcholine, Thiazide diuretics
- See adverse reactions attributed to class:
ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and INTERACTION WITH ALCOHOL
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
